Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

Two weeks later (Day 29) patients begin a maintenance dose of 40 mg every other week. 5-aminosalicylates, corticosteroids, and/or immunomodulatory agents (e.g. 6-mercaptopurine and azathioprine) may be continued during treatment with HUMIRA.

Important Safety Information

Serious infections, sepsis, tuberculosis (TB) and opportunistic infections, including fatalities, have been reported with the use of TNF-blocking agents, including HUMIRA.

Many of these serious infections have occurred in patients also taking other immunosuppressive agents that in addition to their underlying disease could predispose them to infections. Infections have also been reported in patients receiving HUMIRA alone.

Treatment with HUMIRA should not be initiated in patients with active infections. TNF-blocking agents, including HUMIRA, have been associated with reactivation of hepatitis B (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating HUMIRA. The combination of HUMIRA and anakinra is not recommended and patients using HUMIRA should not receive live vaccines.

More cases of malignancies have been observed among patients receiving TNF- blockers, including HUMIRA, compared to control patients in clinical trials. These malignancies, other than lymphoma and non-melanoma skin cancer, were similar in type and number to what would be expected in the general population. There was an approximately three-fold higher rate of lymphoma in combined controlled and uncontrolled open-label portions of HUMIRA clinical trials. The potential role of TNF-blocking therapy in the development of malignancies is not known. TNF-blocking agents, including HUMIRA, have been associated in rare cases with demyelinating disease and severe allergic reactions. Infrequent reports of serious blood disorders have been reported with TNF-blocking agents
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
(Date:6/19/2013)... N.J. , June 19, 2013 /PRNewswire-iReach/ ... Pharma, a new specialty pharmaceutical company dedicated ... of innovative injectable and sustained release drug ... unmet medical needs, today announced the acquisition ... Linker Technology®) platform and associated product pipeline. ...
(Date:6/19/2013)... Calif. , June 19, 2013 ... management solutions, introduced the next-generation of its ... which allows health plans to provide their employer ... populations, health factors, medical and prescription drug claims, ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2
... May 11, 2011 Reportlinker.com announces ... is available in its catalogue: ... 2011 – Generics Market Overview: Patent ... uptake despite tougher market conditions ...
... Daiichi Sankyo announced that applications have been submitted ... of metastatic melanoma to the U.S. Food and Drug ... a pre-marketing application for approval for a companion diagnostic ... also will be registered in Europe.  Vemurafenib is an ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions 5Vemurafenib New Drug Application Submitted to FDA for Melanoma 2Vemurafenib New Drug Application Submitted to FDA for Melanoma 3Vemurafenib New Drug Application Submitted to FDA for Melanoma 4
(Date:6/19/2013)... 2013 Elsevier, a world-leading provider of scientific, ... today the publication of the National Osteoporosis Guideline ... of osteoporosis in postmenopausal women and older men ... in 2009 in Maturitas , the original ... is timely with an additional focus on the ...
(Date:6/19/2013)... Ultimate Medical Academy (UMA) participated in ... on WFLA News Channel 8. Since its inaugural televising ... million for All Children's Hospital in St. Petersburg, Fla. ... of Miracles," marked the second year UMA volunteered for ... the phones during the Telethon, which raised a substantial ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Next ... a premier kids entertainment media organization, and ... games company, will be introducing the Games for ... The 3D game is geared toward students in ... and active lifestyles by rewarding positive choices. The ...
(Date:6/19/2013)... June 19, 2013 Recently, SoCal CEO Magazine ... County held their third in a series of six workshops ... of Respect and helped place the mosaic tiles in their permanent ... her parents, Cathy and Greg Maxwell. , This mural project ... idea that took root over three years ago with the goal ...
(Date:6/19/2013)... June 19, 2013 Maui'd Forever ... dedicated to being an effective and cost effective way ... They have partnered up with Tom Barefoot’s Tours providing ... on most of Hawaii’s activities. , They have just ... can get the lowest prices on their Hawaii activities. ...
Breaking Medicine News(10 mins):Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 2Health News:Ultimate Medical Academy Rallies in Support of All Children's Hospital 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Arc Creates Huge Mosaic Mural to Highlight the Need for Greater Respect of People with Disabilities 2Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2
... June 16 David O. Barbe, M.D., a practicing ... Board of Trustees of the American Medical Association. , ... , "I am honored to be elected to the AMA ... physicians as the AMA and the nation focus on health-care reform." ...
... Food and Drug Administration (FDA) today advised consumers to stop ... cold remedies under the Zicam(R) brand because the use of ... of smell (a condition called anosmia ). ... zinc ingredient, The Quigley Corporation (Nasdaq: QGLY ), ...
... , PHILADELPHIA, June 16 United States Attorney Michael ... Hertz today announced the return of an indictment(1.) against ... Synthes executives, Michael D. Huggins (Huggins), Thomas B. Higgins ... (Walsh), charging them for their involvement in conducting clinical ...
... cholesterol-lowering statin drugs, such as Lipitor (atorvastatin), does not lower ... study of more than 3,000 Group Health patients published online ... Journal ,s June 20 print issue. "Prior research based ... hypefor statins as a way to prevent and treat infections ...
... on Congress to Ban Bonuses For Canceling, Delaying or Denying ... Watchdog called on Congress to ban any health insurance employee ... care to patients based on new evidence made public today. ... on Oversight and Investigations shows that WellPoint, the nation,s largest ...
... Veterans and their Families , , NEW YORK, June ... service members returning from Iraq and Afghanistan. To combat the ... their families from seeking needed psychological help, the Department of ... video from the Defense Centers of Excellence for Psychological Health ...
Cached Medicine News:Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 3Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 2Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 3Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 4Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 5Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 6Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 7Health News:Statins don't lower risk of pneumonia in elderly 2Health News:Largest U.S. Health Insurer Rewarded Employees That Cancelled Coverage of Sick Patients 2Health News:Largest U.S. Health Insurer Rewarded Employees That Cancelled Coverage of Sick Patients 3Health News:Largest U.S. Health Insurer Rewarded Employees That Cancelled Coverage of Sick Patients 4Health News:VIDEO from Medialink and the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury: Department of Defense Launches New Anti-Stigma Campaign 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: